TY - JOUR
T1 - Rehabilitative Training Enhances Therapeutic Effect of Human-iPSC-Derived Neural Stem/Progenitor Cells Transplantation in Chronic Spinal Cord Injury
AU - Shibata, Takahiro
AU - Tashiro, Syoichi
AU - Shibata, Shinsuke
AU - Shinozaki, Munehisa
AU - Shindo, Tomoko
AU - Hashimoto, Shogo
AU - Kawai, Momotaro
AU - Kitagawa, Takahiro
AU - Ago, Kentaro
AU - Matsumoto, Morio
AU - Nakamura, Masaya
AU - Okano, Hideyuki
AU - Nagoshi, Narihito
N1 - Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press.
PY - 2023/3/3
Y1 - 2023/3/3
N2 - Cell transplantation therapy using human-induced pluripotent stem cell-derived neural stem/progenitor cells (hiPSC-NS/PCs) is a new therapeutic strategy for spinal cord injury (SCI). Preclinical studies have demonstrated the efficacy of hiPSC-NS/PCs transplantation in the subacute phase of SCI. However, locomotor recovery secondary to hiPSC-NS/PCs transplantation is limited in the chronic phase, suggesting that additional treatment, including rehabilitative training, is required to ensure recovery. The therapeutic potential of hiPSC-NS/PCs that qualify for clinical application is yet to be fully delineated. Therefore, in this study, we investigated the therapeutic effect of the combined therapy of clinical-grade hiPSC-NS/PCs transplantation and rehabilitative training that could produce synergistic effects in a rodent model of chronic SCI. Our findings indicated that rehabilitative training promoted the survival rate and neuronal differentiation of transplanted hiPSC-NS/PCs. The combination therapy was able to enhance the expressions of the BDNF and NT-3 proteins in the spinal cord tissue. Moreover, rehabilitation promoted neuronal activity and increased 5-HT-positive fibers at the lumbar enlargement. Consequently, the combination therapy significantly improved motor functions. The findings of this study suggest that the combined therapy of hiPSC-NS/PCs transplantation and rehabilitative training has the potential to promote functional recovery even when initiated during chronic SCI.
AB - Cell transplantation therapy using human-induced pluripotent stem cell-derived neural stem/progenitor cells (hiPSC-NS/PCs) is a new therapeutic strategy for spinal cord injury (SCI). Preclinical studies have demonstrated the efficacy of hiPSC-NS/PCs transplantation in the subacute phase of SCI. However, locomotor recovery secondary to hiPSC-NS/PCs transplantation is limited in the chronic phase, suggesting that additional treatment, including rehabilitative training, is required to ensure recovery. The therapeutic potential of hiPSC-NS/PCs that qualify for clinical application is yet to be fully delineated. Therefore, in this study, we investigated the therapeutic effect of the combined therapy of clinical-grade hiPSC-NS/PCs transplantation and rehabilitative training that could produce synergistic effects in a rodent model of chronic SCI. Our findings indicated that rehabilitative training promoted the survival rate and neuronal differentiation of transplanted hiPSC-NS/PCs. The combination therapy was able to enhance the expressions of the BDNF and NT-3 proteins in the spinal cord tissue. Moreover, rehabilitation promoted neuronal activity and increased 5-HT-positive fibers at the lumbar enlargement. Consequently, the combination therapy significantly improved motor functions. The findings of this study suggest that the combined therapy of hiPSC-NS/PCs transplantation and rehabilitative training has the potential to promote functional recovery even when initiated during chronic SCI.
KW - cell transplantation
KW - chronic spinal cord injury
KW - combination treatment
KW - human-induced pluripotent stem cell-derived neural stem/progenitor cells
KW - rehabilitative training
UR - http://www.scopus.com/inward/record.url?scp=85149999153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149999153&partnerID=8YFLogxK
U2 - 10.1093/stcltm/szac089
DO - 10.1093/stcltm/szac089
M3 - Article
C2 - 36647673
AN - SCOPUS:85149999153
SN - 2157-6564
VL - 12
SP - 83
EP - 96
JO - Stem cells translational medicine
JF - Stem cells translational medicine
IS - 2
ER -